Targeting apoptosis in cancer therapy

BA Carneiro, WS El-Deiry - Nature reviews Clinical oncology, 2020 - nature.com
For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Mechanisms of drug resistance in ovarian cancer and associated gene targets

KL Alatise, S Gardner, A Alexander-Bryant - Cancers, 2022 - mdpi.com
Simple Summary When tumors become resistant to chemotherapeutics, alternative
treatment strategies must be explored. Gene targeting provides a personalized and …

[HTML][HTML] ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

VV Prabhu, S Morrow, AR Kawakibi, L Zhou, M Ralff… - Neoplasia, 2020 - Elsevier
ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-
inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G …

The immune landscape of pheochromocytoma and paraganglioma: current advances and perspectives

O Uher, K Hadrava Vanova, D Taïeb… - Endocrine …, 2024 - academic.oup.com
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors derived
from neural crest cells from adrenal medullary chromaffin tissues and extra-adrenal …

Regulation of natural killer cell activity by glucocorticoids, serotonin, dopamine, and epinephrine

S Capellino, M Claus, C Watzl - Cellular & molecular immunology, 2020 - nature.com
The immune system and the nervous system are highly complex organs composed of
various different cells that must interact with each other for proper function of the system …

ONC201 (dordaviprone) in recurrent H3 K27M–mutant diffuse midline glioma

I Arrillaga-Romany, SL Gardner, Y Odia… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Histone 3 (H3) K27M–mutant diffuse midline glioma (DMG) has a dismal
prognosis with no established effective therapy beyond radiation. This integrated analysis …

Therapeutic targeting of TRAIL death receptors

F Di Cristofano, A George, V Tajiknia… - Biochemical Society …, 2023 - portlandpress.com
The discovery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) along with
its potent and selective antitumor effects initiated a decades-long search for therapeutic …

Mitochondrial quality control proteases and their modulation for cancer therapy

J Zhang, W Qiao, Y Luo - Medicinal Research Reviews, 2023 - Wiley Online Library
Mitochondria, the main provider of energy in eukaryotic cells, contains more than 1000
different proteins and is closely related to the development of cells. However, damaged …

Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets

J **a, S Li, S Liu, L Zhang - MedComm, 2023 - Wiley Online Library
The family of aldehyde dehydrogenases (ALDHs) contains 19 isozymes and is involved in
the oxidation of endogenous and exogenous aldehydes to carboxylic acids, which …

Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy

SL Gardner, RS Tarapore, J Allen… - Neuro-Oncology …, 2022 - academic.oup.com
Background ONC201, a dopamine receptor D2 (DRD2) antagonist and caseinolytic
protease P (ClpP) agonist, has induced durable tumor regressions in adults with recurrent …